Drug Trial Radar · NCT06581380
JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Sep 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
394
Planned (sponsor's estimate)
Start
Sep 16, 2024
Primary completion
Nov 16, 2027
Study completion Apr 16, 2028
Sponsor
- Lead sponsor
- JenKem Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was designed to compare the efficacy and safety of JK-1201I with Topotecan in patients with relapsed extensive stage small cell lung cancer (ES SCLC).
Conditions
- Small Cell Lung Cancer
Interventions
JK-1201IDrug
JK-1201I will be administered as an IV infusion at dose of 180mg/m2 on Day 1 of each 21-day cycle.
TopotecanDrug
Topotecan will be administered per drug label.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: From the date of randomization to the date of death due to any cause; Up to approximately 3.5 years.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.